About THE INSTITUTE

Contents

Summary of the Scientific and Business Plan
Prepared by Garth L. Nicolson, Ph.D., M.D. (H)

The Institute Mission

The mission of the Institute for Molecular Medicine is to contribute to the understanding of and the prevention and cure of catastrophic human chronic diseases, such as autoimmune diseases, fatigue illnesses, rheumatic diseases, cancer, AIDS, and infectious and genetic diseases. This will be accomplished through innovative basic and translational research programs.
(Top of Page)

Scientific Goal of The Institute

The goal of the Institute for Molecular Medicine is to apply basic and translational molecular research approaches to better understand and eventually treat catastrophic human chronic diseases.
(Top of Page)

Scientific Vision of The Institute

The Institute for Molecular Medicine is building scientific programs that interface with clinical programs by recruiting outstanding scientists and physicians to work in a multidisciplinary scientific environment designed for maximum innovation and productivity.
(Top of Page)

The Institute Plan

The Plan of the Institute for Molecular Medicine is to be conducted in phases. In first phase, the Institute has been founded using private and institutional donations (1996), and the initial scientists were chosen to lead the Institute, which was established in Irvine, California. In the next phase the Institute occupied a building at 16371 Gothard Street, Huntington Beach, California. This is our current address is shown on the homepage.
(Top of Page)

Proposed Scientific Programs of The Institute

The Institute for Molecular Medicine will focus on scientific programs that are critical to our understanding of the basic biology, diagnosis and treatment of catastrophic chronic human diseases. One-half of the initial departments will be translational, that is, they will be engaged in translating basic research into the clinic and will involve the development of new assays, procedures and treatments are useful in the diagnosis and treatment of chronic diseases. They will also conduct IRB-approved clinical trials. The scientific programs will be built around academic research departments. The initial scientific departments at The Institute for Molecular Medicine are:

Basic Science Departments

Translational Science Departments

  • Molecular Immunology
  • Molecular Pathology

Other Departments

  • Grants and Scholarship Administration
  • Institute Administration and Legal Services

(Top of Page)

Administrative Programs of The Institute

The Institute for Molecular Medicine is building appropriate administrative structures and programs that aid and assist in the Institute's mission. The business programs of the Institute were established by the Institute's Business Board. Such programs include centralized administrative structures rather than Departmental administrative structures to increase efficiency and reduce administrative costs. Where ever possible, computers are used to link various members of the Institute with each other and with administrative programs as well as with regional Universities. The scientific programs of the Institute will be centralized to some degree by the Institute's Scientific Advisory Board. Centralized core research facilities are being established to provide centralized equipment and more efficient services, such as those required for tissue culture media and glassware preparation, molecular biology services, animal care and other services.
(Top of Page)

Advisory Boards of The Institute

Institute Scientific Advisory Board: The academic decisions of the Institute, such as research appointments and promotions, will be overseen by the Chief Scientific Officer and an Institute Scientific Advisory Board composed of the Chief Scientific Officer, the Deputy Scientific Officer and the Department Chairs. The Institute Scientific Advisory Board will assist the Chief Scientific Officer in making academic decisions and in determining the future scientific plans of the Institute.

External Scientific Advisory Board: An External Scientific Advisory Board is being appointed by and will report to the Board of Directors and the Officers of the Institute. It will be charged to evaluate Institute personnel and programs, provide direction and advise the Chief Scientific Officer.

Business Advisory Board: The business decisions of the Institute, such as business planning, evaluation and implementation, will be overseen by the Chairman of the Board, the President, and other Officers using an Institute Business Advisory Board composed of the Chairman of the Board, President, Vice Presidents, Secretary-Treasurer, Chief Scientific Officer and other Officers of the Institute as deemed necessary, along with members of the Board of Directors and other members chosen at large.

Institutional Review Board: Although the institute established an IRB committee in 1998, it was disbanded in 2003 in favor of review by independent IRB committees. This was done to make sure that IRB review and approvals would be completely independent of Institute personnel.

(Top of Page)

Educational Programs of The Institute

The Institute for Molecular Medicine is currently involved in laboratory training of post-graduate researchers and physicians and has U. S. Department of State approval for its international program. Applicants to these programs can contact a faculty sponsor to obtain further information on availability of positions and various research areas in the program.

 

Policy on Financial Interests Related to U.S. Public Health Service (USPHS) Sponsored Projects for Promoting Objectivity in Research

On August 23, 2012 IMM implemented the 2011 USPHS regulations on Responsibility of Applicants for Promoting Objectivity in Research for which USPHS Funding is Sought (USPHS regulations). The USPHS regulations were designed to promote objectivity by establishing standards that provide a reasonable expectation that the design, conduct and reporting of Public Health Service funded research will be free from bias resulting from any Investigator’s financial conflicts of interest. This policy is based on the U.S. Department of Health and Human Services (DHHS) Objectivity in Research,” Code of Federal Regulations (42 C.F.R. Part 50, subpart F) and became effective on August 24, 2012. It applies to all IMM investigators who are involved in research supported by U.S. governmental organizations.

The Board of Directors of IMM review disclosures of financial conflict of interest and significant financial interests and their relationship to USPHS (including any organizational unit, agency or entity of the DHHS and any non-USPHS entity adopting the USPHS regulations on Responsibility of Applicants for Promoting Objectivity in Research for which USPHS Funding is Sought) funded research and determine whether any significant financial interests constitute a financial conflict of interest (FCOI). The policy is explained in the following attachment. pdf doc


(Top of Page)